News & articles

August 1, 2015 We are pleased to announce that effective 8/1/2015, Michelle Woehrle has assumed the role of Executive Director of the MPN Research Foundation. Michelle began working with the Foundation in 2007, and since that time her role has expanded to include oversight of office administration, financial management, grant program support and coordination of… Read More »EXECUTIVE DIRECTOR

June 25, 2015 Galena presented Phase 2 data on Gale-401: PHASE 2 STUDY OF A NOVEL CONTROLLED-RELEASE FORMULATION OF ANAGRELIDE (GALE-401) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-RELATED THROMBOCYTOSIS Prof. Dr. Heinz Gisslinger presented a poster on CALR and ASXL1 mutations: IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY… Read More »2015 EHA NEWS ON MPNS

On August 19, 2014, Julie Libon was diagnosed with Myelofibrosis. She learned that MF is a rare blood cancer that affects approximately 16,500 to 18,000 people in the United States with no cure and no treatments to slow down the progression of this disease. After her diagnosis, she and her family felt compelled to act.… Read More »WITH RESEARCH THERE IS HOPE

une 5, 2015 The American Society of Clinical Oncology has its big meeting each year in Chicago in early June. In the past solid tumor cancers have received the most attention, saving blood cancer announcements for the American Society of Hematology meeting where the focus is more narrow. This year, however, was different, with big… Read More »2015 ASCO NEWS

February 25, 2015 Last week we issued a call for proposals for our 2015 grant program, which we run with with some help from the Leukemia & Lymphoma Society, but is largely funded by patients around the world. Our place in the growing world of MPN research is to seek out new ideas that are… Read More »PROMISE AND POSSIBILITY

February 12, 2015 The order in which someone with an MPN acquires a genetic mutation may effect their prognosis, says an article published today in the New England Journal of Medicine. Researchers from the U.K. were able to determine the order in which people with myeloproliferative neoplasms acquired the TET2 and JAK2 mutations, which influenced… Read More »NEJM STUDY ON THE EFFECT OF MUTATION ORDER IN MPNS

February 4, 2015 Today is World Cancer Day. In honor of this day recognizing the struggle of cancer patients everywhere we’re asking people to give a gift for MPN research that will help identify better treatments and eventually a cure for polycythemia vera, essential thrombocythemia and myelofibrosis. Click here to make a contribution today! Bonus: if you make a contribution… Read More »2015 WORLD CANCER DAY

Researchers at the National Center for Cardiovascular Research (CNIC) in Spain found that estrogens play a role in regulating the active of blood stem cells from bone marrow. Simon Mendez-Ferrer, Jürg Schwaller and Radek Skoda published a paper in Cell which demonstrated that tamoxifen – an approved breast cancer drug – was effective in blocking… Read More »TAMOXIFEN POSSIBLE TREATMENT FOR MYELOPROLIFERATIVE NEOPLASMS

December 4, 2014 Today Jakafi became the first FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Approved for use to treat symptoms of myelofibrosis in 2011, Jakafi’s new use is intended to treat polycythemia vera patients who have an inadequate response to or… Read More »JAKAFI APPROVED FOR USE IN HYDROXYUREA-RESISTANT POLYCYTHEMIA VERA

The MPN Research Foundation is proud to congratulate Gary Gilliland today on his appointment as Director of the Fred Hutchinson Cancer Research Center in Seattle. His focus will be on immunotherapeutic treatments. Dr. Gilliland was a long time grantee of the Foundation, and headed one of the labs that originally discovered the JAK2 mutation was… Read More »GARY GILLILAND NAMED DIRECTOR AT THE FRED HUTCHINSON CANCER RESEARCH CENTER